2-[1-({[(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetic acid

• ChemBase编号: 354
• 分子式: C35H36ClNO3S
• 平均质量: 586.18324
• 单一同位素质量: 585.2104427
• SMILES: Clc1cc2nc(/C=C/c3cc([C@H](SCC4(CC4)CC(=O)O)CCc4c(C(O)(C)C)cccc4)ccc3)ccc2cc1
• Canonical SMILES: OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1
• InChI: InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
• InChIKey: UCHDWCPVSPXUMX-TZIWLTJVSA-N

名称和登记号

名称

• IUPAC标准名: 2-[1-({[(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetic acid
• IUPAC传统名: montelukast
• 商标名: Singulair; Singular; Montair
• 别名: Montelukast

登记号

• CAS号: 158966-92-8
• PubChem SID: 160963817; 46505585
• PubChem CID: 5281040

理论计算性质

JChem

• Acid pKa: 4.400609
• 质子受体: 4
• 质子供体: 2
• LogD (pH = 5.5): 7.5461497
• LogD (pH = 7.4): 5.7954516
• Log P: 8.493533
• 摩尔折射率: 169.5039 cm^3
• 极化性: 67.09314 Å^3
• 极化表面积: 70.42 Å^2
• 可自由旋转的化学键: 12
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 7.25
• LOG S: -7.85
• 溶解度: 8.20e-06 g/l

分子性质

理化性质

• 疏水性(logP): 7.9

详细说明

DrugBank - DB00471

• Drug Groups: approved
• Description: Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific locus of operation, it does not interact with other allergy medications such as theophylline. Montelukast is marketed in United States and many other countries by Merck & Co. with the brand name Singulair?. It is available as oral tablets, chewable tablets, and oral granules. In India and other countries, it is also marketed under the brand name Montair®, produced by Indian company Cipla.
• Indication: For the treatment of asthma
• Pharmacology: Montelukast, like zafirlukast, is a leukotriene receptor antagonist used as an alternative to anti-inflammatory medications in the management and chronic treatment of asthma and exercise-induced bronchospasm (EIB). Unlike zafirlukast, montelukast does not inhibit CYP2C9 or CYP3A4 and is, therefore, not expected to affect the hepatic clearance of drugs metabolized by these enzymes.
• Toxicity: Side effects include headache, abdominal or stomach pain, cough, dental pain, dizziness, fever, heartburn, skin rash, stuffy nose, weakness or unusual tiredness.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic
• Absorption: Rapidly absorbed following oral administration (bioavailability is 64%)
• Half Life: 2.7-5.5 hours
• Protein Binding: 99% (to plasma proteins)
• Elimination: Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.
• Distribution: * 8 to 11 L
• Clearance: * 45 mL/min [healthy adults]
• External Links: Wikipedia; RxList; Drugs.com